pp-067 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
Japan
GMP approvals
Japan
Comments
Indication: Advanced or metastatic osteosarcoma and other solid tumors in patients who have progressed after standard treatments.
Clinical stage: Phase III in osteosarcoma, with additional early-phase studies in multiple solid tumor indications.
Modality: Small-molecule oral therapy.
Mechanism / Target: Multi-kinase inhibition of FLT3, MET, AXL and related pathways that drive tumor growth, angiogenesis, and survival.
Route / form: Oral tablets.
Differentiation: Broad multi-target profile designed to overcome resistance to single-target TKIs, offering dual effects on tumor proliferation and angiogenesis with potential applicability across diverse solid tumors.
Manufacturer #38605
A research-driven pharma company developing therapies across oncology and other major diseases. It advances innovative medicines through global R&D and strategic alliances. The organization emphasizes high-quality manufacturing and patient impact.